Mirus Capital Advisors Serves as Financial Advisor to Keensight Capital on its Acquisition of a Majority Stake in Isto Biologics

Mirus Capital Advisors, Inc., a leading independent middle-market investment banking firm, is pleased to announce that it has advised Keensight Capital, a leading European Growth Buyout investor with deep expertise in Technology and Healthcare, on its acquisition of a majority stake in Isto Biologics, from Thompson Street Capital Partners.

Founded in 2016, Isto Biologics is a developer and manufacturer of regenerative orthobiologic products to help patients heal faster. Its best-in-class product offering covers six functional areas of unique bone graft solutions and are used in 15,000 surgical procedures per month, primarily in the United States. The company has seen rapid growth—both organically and through strategic M&A—with the support of Thompson Street Capital Partners including 2023’s acquisition of Advanced Biologics, and the acquisition of TheraCell in 2022.

With a long track record of investments in the MedTech space, Keensight Capital will leverage its extensive international network, experience, and deep sector expertise to accelerate Isto’s growth strategy, both organically and through acquisitions, and further grow the company into a global leader in biomaterials for tissue regeneration.

Amit Karna and David Piccoli, Partners at Keensight Capital, stated, “We have been investors in the biomaterials, orthopedics, spine and bone repair segments for over 20 years, and have been tracking Isto Biologics specifically for over 5 years. Isto is the perfect example of a Keensight healthcare investment: a company that offers proven technology which is improving patient lives, while delivering sustainable and profitable growth. We are very excited to support Isto with its continued domestic success and international expansion.”

Brendan Kiernan, partner at Mirus Capital Advisors, added, “We are pleased to have had the opportunity to advise Keensight on this transaction. It further cements our position as a leading advisor in the orthobiologics sector. Our client is an ideal partner to facilitate Isto Biologics’ ambitious growth plans.”

About Keensight Capital

Keensight Capital (“Keensight”), one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. With over 25 years of experience and €5.5bn of assets under management, Keensight Capital’s team of seasoned professionals leverages their differentiated private equity experience to invest in profitably growing companies generating revenues in the range of €10 million to €400 million. Drawing on its expertise in the Technology and Healthcare sectors, Keensight identifies the best investment opportunities in Europe and works closely with the management teams providing capital, strategic guidance and operational support. Keensight operates in more than 90 countries across the globe with a presence in Paris, London, Boston, and Singapore. www.keensight.com

About Thompson Street Capital Partners

Thompson Street Capital Partners is a middle-market private equity firm that helps transform already exceptional businesses into market leaders. Based in St. Louis, Missouri, TSCP invests globally in the life sciences and healthcare, software and technology, business and consumer services and products sectors. TSCP partners with management teams to increase value by accelerating growth, both organically and via complementary acquisitions. www.tscp.com

About Isto Biologics

Isto Biologics is a leading biologics and cellular therapy company. Focused on Helping Patients Heal Faster™ through innovative solutions for bone regeneration and cell-based therapies, Isto prides itself on providing the most complete and innovative biologics offerings on the market. From its inception around Isto’s flagship autologous cellular solution, the Magellan® Autologous Platelet Separator, Isto has grown through developing complete bone grafting options touching all categories of bone grafts; InQu® Bone Graft Extender & Substitute; Influx™ Advanced Allograft Technology including Fibrant™ Functional Allograft Constructs, SPARC Integrative Bone Matrix, and ProteiOS Allograft-Derived Proteins. www.istobiologics.com

About Mirus Capital Advisors, Inc.

As a mid-market investment bank focused on mergers and acquisitions, Mirus drives successful deals for companies in the technology, industrial, consumer products, business services, and healthcare sectors. Mirus has proven time and again that its deep industry expertise, focus on relationships, thorough preparation, and unwavering commitment to every deal lead to meaningful accomplishments for business owners. For more, visit www.merger.com

Note: Mirus Capital Advisors acted as the exclusive financial advisor to TheraCell, Inc. in its sale to Isto Biologics.